Literature DB >> 2965430

Inhibition of human factor VIIa-tissue factor activity by placental anticoagulant protein.

S Kondo1, M Noguchi, T Funakoshi, K Fujikawa, W Kisiel.   

Abstract

Previous studies indicated that human placental anticoagulant protein, a member of the lipocortin family, prolonged the clotting time of normal plasma when clotting was induced by brain thromboplastin or by kaolin in the presence of cephalin and calcium. Using a two-stage amidolytic assay to assess factor X activation and a tritiated peptide release assay to assess factor IX activation, we have examined the ability of purified preparations of placental anticoagulant protein (Mr = 36.5 kDa) to inhibit the activation of either factor X or factor IX by a complex of human factor VIIa-tissue factor. Placental anticoagulant protein markedly inhibits factor X and factor IX activation by factor VIIa-tissue factor in a non-competitive manner with Ki values of 40 nM and 70 nM, respectively. Placental anticoagulant protein had no effect on factor Xa amidolytic activity, and its inhibitory activity was not diminished by prior incubation with antibody raised against partially purified plasma extrinsic pathway inhibitor. Binding of placental anticoagulant protein to phospholipid vesicles, crude tissue factor and purified, relipidated human brain tissue factor apoprotein was observed only in the presence of calcium ions. These results indicate that placental anticoagulant protein is a potent factor VIIa-tissue factor inhibitor and suggests that its mechanism of action involves binding to the phospholipid portion of the tissue factor lipoprotein.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2965430     DOI: 10.1016/0049-3848(87)90402-6

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  9 in total

1.  An anticoagulant dermatan sulfate proteoglycan circulates in the pregnant woman and her fetus.

Authors:  M Andrew; L Mitchell; L Berry; B Paes; M Delorme; F Ofosu; R Burrows; B Khambalia
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

2.  A 32 kDa lipocortin from human mononuclear cells appears to be identical with the placental inhibitor of blood coagulation.

Authors:  B Rothhut; C Coméra; S Cortial; P Y Haumont; K H Diep Le; J C Cavadore; J Conard; F Russo-Marie; F Lederer
Journal:  Biochem J       Date:  1989-11-01       Impact factor: 3.857

3.  Phospholipid binding of antiphospholipid antibodies and placental anticoagulant protein.

Authors:  L R Sammaritano; A E Gharavi; C Soberano; R A Levy; M D Lockshin
Journal:  J Clin Immunol       Date:  1992-01       Impact factor: 8.317

Review 4.  Tissue factor as a tumor procoagulant.

Authors:  L V Rao
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

5.  Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant.

Authors:  P M Sandset; B J Warn-Cramer; L V Rao; S L Maki; S I Rapaport
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-01       Impact factor: 11.205

Review 6.  Annexin II tetramer: structure and function.

Authors:  D M Waisman
Journal:  Mol Cell Biochem       Date:  1995 Aug-Sep       Impact factor: 3.396

7.  Use of annexin-V to demonstrate the role of phosphatidylserine exposure in the maintenance of haemostatic balance by endothelial cells.

Authors:  C Ravanat; G Archipoff; A Beretz; G Freund; J P Cazenave; J M Freyssinet
Journal:  Biochem J       Date:  1992-02-15       Impact factor: 3.857

8.  Detection, purification and identification of an endogenous inhibitor of L-Dopa decarboxylase activity from human placenta.

Authors:  Alice-Georgia Vassiliou; Emmanuel G Fragoulis; Dido Vassilacopoulou
Journal:  Neurochem Res       Date:  2008-11-13       Impact factor: 3.996

Review 9.  Placental damage in pregnancies with systemic lupus erythematosus: A narrative review.

Authors:  Aleida Susana Castellanos Gutierrez; Francesc Figueras; Diana M Morales-Prieto; Ekkehard Schleußner; Gerard Espinosa; Núria Baños
Journal:  Front Immunol       Date:  2022-08-17       Impact factor: 8.786

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.